<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02582801</url>
  </required_header>
  <id_info>
    <org_study_id>Molecular Imaging</org_study_id>
    <nct_id>NCT02582801</nct_id>
  </id_info>
  <brief_title>Clinical Research of 18F-Alfatide Ⅱ PET/CT in Breast Cancer</brief_title>
  <official_title>18F-Alfatide Ⅱ PET/CT in the Diagnosis and Treatment Response Evaluation of Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiang Wu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jinling Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      18F-Alfatide Ⅱ PET/CT in breast cancer patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to assess the clinical application of 18F-Alfatide Ⅱ PET/CT in the
      diagnosis and treatment response monitoring of breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum standardized uptake value (SUVmax)</measure>
    <time_frame>1 day</time_frame>
    <description>the uptake intensity of lesions</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perform 18F-Alfatide Ⅱ PET/CT in breast cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>benign breast lesions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Perform 18F-Alfatide Ⅱ PET/CT in patients with benign breast lesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-Alfatide Ⅱ PET/CT</intervention_name>
    <description>Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min</description>
    <arm_group_label>breast cancer</arm_group_label>
    <arm_group_label>benign breast lesions</arm_group_label>
    <other_name>18F-AlF-NOTA-E[PEG4-c(RGDfk)]2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients have been suspected or diagnosed with breast cancer and they have not
             received any treatment; It must fulfill the ethical requirements and subjects have
             signed an informed consent.

        Exclusion Criteria:

          -  Pregnancy or nursing mothers; Those patients accompanied by other serious diseases
             such as cardiac functional insufficiency, hepatic and renal function insufficiency.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guangming Lu, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Jinling Hospital, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiang Wu, MD</last_name>
    <phone>86-25-80860319</phone>
    <email>Wudoc@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Wu, MD</last_name>
      <phone>86-25-80860319</phone>
      <email>Wudoc@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Yu C, Pan D, Mi B, Xu Y, Lang L, Niu G, Yang M, Wan W, Chen X. (18)F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2021-8. doi: 10.1007/s00259-015-3118-2. Epub 2015 Jul 1.</citation>
    <PMID>26121930</PMID>
  </reference>
  <reference>
    <citation>Wang SY, Bao X, Wang MW, Zhang YP, Zhang YJ, Zhang JP. Radiation dosimetry estimates of (18)F-alfatide II based on whole-body PET imaging of mice. Appl Radiat Isot. 2015 Nov;105:1-5. doi: 10.1016/j.apradiso.2015.07.013. Epub 2015 Jul 13.</citation>
    <PMID>26218449</PMID>
  </reference>
  <reference>
    <citation>Mi B, Yu C, Pan D, Yang M, Wan W, Niu G, Chen X. Pilot Prospective Evaluation of (18)F-Alfatide II for Detection of Skeletal Metastases. Theranostics. 2015 Jul 12;5(10):1115-21. doi: 10.7150/thno.12938. eCollection 2015.</citation>
    <PMID>26199649</PMID>
  </reference>
  <reference>
    <citation>Wu C, Yue X, Lang L, Kiesewetter DO, Li F, Zhu Z, Niu G, Chen X. Longitudinal PET imaging of muscular inflammation using 18F-DPA-714 and 18F-Alfatide II and differentiation with tumors. Theranostics. 2014 Feb 26;4(5):546-55. doi: 10.7150/thno.8159. eCollection 2014.</citation>
    <PMID>24672585</PMID>
  </reference>
  <reference>
    <citation>Guo J, Guo N, Lang L, Kiesewetter DO, Xie Q, Li Q, Eden HS, Niu G, Chen X. (18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy. J Nucl Med. 2014 Jan;55(1):154-60. doi: 10.2967/jnumed.113.122069. Epub 2013 Nov 14.</citation>
    <PMID>24232871</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Jinling Hospital, China</investigator_affiliation>
    <investigator_full_name>Jiang Wu</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <keyword>PET/CT</keyword>
  <keyword>Alfatide Ⅱ</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

